Optical Coherence Tomography Angiography Biomarkers Predict Anatomical Response to Bevacizumab in Diabetic Macular Edema

References

• Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:4–14. doi:10.1016/j.diabres.2009.10.007
   PubMed Web of Science ®Google Scholar
• Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol. 2007;14:179–183. doi:10.1080/09286580701396720
   PubMed Web of Science ®Google Scholar
• Zhang X, Saaddine JB, Chou CF, et al. Prevalence of diabetic retinopathy in the United States, 2005–2008. JAMA. 2010;304:649–656. doi:10.1001/jama.2010.1111
   PubMed Web of Science ®Google Scholar
• Hegazi R, El-Gamal M, Abdel-Hady N, Hamdy O. Epidemiology of and risk factors for type 2 diabetes in Egypt. Ann Glob Health. 2015;81:814–820. doi:10.1016/j.aogh.2015.12.011
   PubMed Web of Science ®Google Scholar
• Herman WH, Aubert RE, Engelgau MM, et al. Diabetes mellitus in Egypt: glycaemic control and microvascular and neuropathic complications. Diabet Med. 1998;15:1045–1051. doi:10.1002/(SICI)1096-9136(1998120)15:12<1045::AID-DIA696>3.0.CO;2-L
   PubMed Web of Science ®Google Scholar
• Wells JA, Glassman AR Ayala AR, et al. Diabetic retinopathy clinical research network, aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372:1193–1203.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789–801. doi:10.1016/j.ophtha.2011.12.039
   PubMed Web of Science ®Google Scholar
• Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615–625. doi:10.1016/j.ophtha.2011.01.031
   PubMed Web of Science ®Google Scholar
• Ramsey DJ, Poulin SJ, LaMonica LC, et al. Early conversion to aflibercept for persistent diabetic macular edema results in better visual outcomes and lower treatment costs. Clin Ophthalmol. 2021;15:31–39. doi:10.2147/OPTH.S286665
   Web of Science ®Google Scholar
• Lazic R, Lukic M, Boras I, et al. Treatment of anti-vascular endothelial growth factor-resistant diabetic macular edema with dexamethasone intravitreal implant. Retina. 2014;34:719–724. doi:10.1097/IAE.0b013e3182a48958
   PubMed Web of Science ®Google Scholar
• Fickweiler W, Schauwvlieghe AS, Schlingemann RO, et al. Predictive value of optical coherence tomographic features in the bevacizumab and ranibizumab in patients with Diabetic Macular Edema (BRDME) Study. Retina. 2018;38:812–819. doi:10.1097/IAE.0000000000001626
   Web of Science ®Google Scholar
• Sun JK, Lin MM, Lammer J, et al. Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with center-involved diabetic macular edema. JAMA Ophthalmol. 2014;132:1309–1316. doi:10.1001/jamaophthalmol.2014.2350
   PubMed Web of Science ®Google Scholar
• Seo KH, Yu SY, Kim M, Kwak HW. Visual and morphologic outcomes of intravitreal ranibizumab for diabetic macular edema based on optical coherence tomography patterns. Retina. 2016;36:588–595. doi:10.1097/IAE.0000000000000770
   PubMed Web of Science ®Google Scholar
• AttaAllah HR, Mohamed AAM, Ali MA. Macular vessels density in diabetic retinopathy: quantitative assessment using optical coherence tomography angiography. Int Ophthalmol. 2019;39:1845–1859. doi:10.1007/s10792-018-1013-0
   Web of Science ®Google Scholar
• Alam M, Zhang Y, Lim JI, Chan RV, Yang M, Yao X. Quantitative optical coherence tomography angiography features for objective classification and staging of diabetic retinopathy. Retina. 2018;40:322–332. doi:10.1097/IAE.0000000000002373
   Web of Science ®Google Scholar
• Lee J, Moon BG, Cho AR, Yoon YH. Optical coherence tomography angiography of DME and its association with anti-VEGF treatment response. Ophthalmology. 2016;123:2368–2375. doi:10.1016/j.ophtha.2016.07.010
   PubMed Web of Science ®Google Scholar
• Hsieh YT, Alam MN, Le D, et al. OCT angiography biomarkers for predicting visual outcomes after ranibizumab treatment for diabetic macular edema. Ophthalmol Retina. 2019;3:826–834. doi:10.1016/j.oret.2019.04.027
   Google Scholar
• Ashraf M, Sampani K, Abu-Qamar O, et al. Optical coherence tomography angiography projection artifact removal: impact on capillary density and interaction with diabetic retinopathy severity. Transl Vis Sci Technol. 2020;9:10. doi:10.1167/tvst.9.7.10
   Web of Science ®Google Scholar
• Campbell JP, Zhang M, Hwang TS, et al. Detailed vascular anatomy of the human retina by projection-resolved optical coherence tomography angiography. Sci Rep. 2017;7:42201. doi:10.1038/srep42201
   PubMed Web of Science ®Google Scholar
• Elnahry AG, Abdel-Kader AA, Raafat KA, Elrakhawy K. Evaluation of changes in macular perfusion detected by optical coherence tomography angiography following 3 intravitreal monthly bevacizumab injections for diabetic macular edema in the IMPACT Study. J Ophthalmol. 2020;2020:5814165. doi:10.1155/2020/5814165
   PubMed Web of Science ®Google Scholar
• Pieramici DJ, Wang PW, Ding B, Gune S. Visual and anatomic outcomes in patients with diabetic macular edema with limited initial anatomic response to ranibizumab in RIDE and RISE. Ophthalmology. 2016;123:1345–1350. doi:10.1016/j.ophtha.2016.02.007
   PubMed Web of Science ®Google Scholar
• Parravano M, Costanzo E, Querques G. Profile of non-responder and late responder patients treated for diabetic macular edema: systemic and ocular factors. Acta Diabetol. 2020;57:911–921. doi:10.1007/s00592-020-01496-7
   PubMed Web of Science ®Google Scholar
• Kim YK, An Y, Park SP. Intraocular and interocular differences in parafoveal vascular density in diabetic patients without diabetic retinopathy. Retina. 2021;41:170–180. doi:10.1097/IAE.0000000000002781
   Web of Science ®Google Scholar
• Bressler SB, Ayala AR, Bressler NM, et al. Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment. JAMA Ophthalmol. 2016;134:278–285. doi:10.1001/jamaophthalmol.2015.5346
   PubMed Web of Science ®Google Scholar
• Wessel MM, Nair N, Aaker GD, Ehrlich JR, D’Amico DJ, Kiss S. Peripheral retinal ischaemia, as evaluated by ultra-widefield fluorescein angiography, is associated with diabetic macular oedema. Br J Ophthalmol. 2012;96:694–698. doi:10.1136/bjophthalmol-2011-300774
   PubMed Web of Science ®Google Scholar
• Takamura Y, Tomomatsu T, Matsumura T, et al. The effect of photocoagulation in ischemic areas to prevent recurrence of diabetic macular edema after intravitreal bevacizumab injection. Invest Ophthalmol Vis Sci. 2014;55:4741–4746. doi:10.1167/iovs.14-14682
   PubMed Web of Science ®Google Scholar
• Duh EJ, Sun JK, Stitt AW. Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. JCI Insight. 2017;2:e93751. doi:10.1172/jci.insight.93751
   PubMed Web of Science ®Google Scholar
• Busch C, Wakabayashi T, Sato T, et al. Retinal microvasculature and visual acuity after intravitreal aflibercept in diabetic macular edema: an optical coherence tomography angiography study. Sci Rep. 2019;9:156. doi:10.1038/s41598-018-38248-1
   Web of Science ®Google Scholar
• Elnahry AG, Ramsey DJ. Optical coherence tomography angiography imaging of the retinal microvasculature is unimpeded by macular xanthophyll pigment. Clin Exp Ophthalmol. 2020;48:1012–1014. doi:10.1111/ceo.13824
   PubMed Web of Science ®Google Scholar
• Statler B, Conti TF, Conti FF, et al. Twenty-four-month OCTA assessment in diabetic patients undergoing fixed-interval intravitreal aflibercept therapy. Ophthalmic Surg Lasers Imaging Retina. 2020;51:448–455. doi:10.3928/23258160-20200804-05
   Web of Science ®Google Scholar
• Elnahry AG, Abdel-Kader AA, Habib AE, Elnahry GA, Raafat KA, Elrakhawy K. Review on recent trials evaluating the effect of intravitreal injections of anti-VEGF agents on the macular perfusion of diabetic patients with diabetic macular edema. Rev Recent Clin Trials. 2020;15:188–198. doi:10.2174/1574887115666200519073704
   PubMed Web of Science ®Google Scholar
• Sorour OA, Sabrosa AS, Alibhai AY, et al. Optical coherence tomography angiography analysis of macular vessel density before and after anti-VEGF therapy in eyes with diabetic retinopathy. Int Ophthalmol. 2019;39:2361–2371. doi:10.1007/s10792-019-01076-x
   Web of Science ®Google Scholar
• Elnahry AG, Elnahry GA. Optical coherence tomography angiography of macular perfusion changes after anti-VEGF therapy for diabetic macular edema: a systematic review. J Diabetes Res. 2021;2021:6634637. doi:10.1155/2021/6634637
   PubMed Web of Science ®Google Scholar
• Sorour OA, Elsheikh M, Chen S, et al. Mean macular intercapillary area in eyes with diabetic macular oedema after anti-vascular endothelial growth factor therapy and its association with treatment response. Clin Exp Ophthalmol. 2021;49:714–723. doi:10.1111/ceo.13966
   PubMed Web of Science ®Google Scholar
• Li A, Rieveschl NB, Conti FF, et al. Long-term assessment of macular atrophy in patients with age-related macular degeneration receiving anti-vascular endothelial growth factor. Ophthalmol Retina. 2018;2:550–557. doi:10.1016/j.oret.2017.10.010
   PubMedGoogle Scholar
• Pieramici D, Singh RP, Gibson A, et al. Outcomes of diabetic macular edema eyes with limited early response in the VISTA and VIVID studies. Ophthalmol Retina. 2018;2:558–566. doi:10.1016/j.oret.2017.10.014
   Google Scholar